These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16728366)

  • 1. Treatment of visceral leishmaniasis.
    Ozsoylu S
    Pediatr Hematol Oncol; 2006; 23(5):449-51; author reply 455-7. PubMed ID: 16728366
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug policy for visceral leishmaniasis: a cost-effectiveness analysis.
    Vanlerberghe V; Diap G; Guerin PJ; Meheus F; Gerstl S; Van der Stuyft P; Boelaert M
    Trop Med Int Health; 2007 Feb; 12(2):274-83. PubMed ID: 17300636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti leishmanial therapy--the changing scene.
    Bichile LS
    J Assoc Physicians India; 1994 Sep; 42(9):682-3. PubMed ID: 7883657
    [No Abstract]   [Full Text] [Related]  

  • 4. Visceral leishmaniasis: more prevalent and more problematic.
    Baily GG; Nandy A
    J Infect; 1994 Nov; 29(3):241-7. PubMed ID: 7884216
    [No Abstract]   [Full Text] [Related]  

  • 5. Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.
    Murray HW
    Expert Rev Anti Infect Ther; 2004 Apr; 2(2):279-92. PubMed ID: 15482193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug regimens for visceral leishmaniasis in Mediterranean countries.
    Gradoni L; Soteriadou K; Louzir H; Dakkak A; Toz SO; Jaffe C; Dedet JP; Campino L; Cañavate C; Dujardin JC
    Trop Med Int Health; 2008 Oct; 13(10):1272-6. PubMed ID: 18764817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of visceral leishmaniasis with fluconazole and allopurinol in a patient with renal failure.
    Colakoglu M; Yaylali GF; Colakoglu NY; Yilmaz M
    Scand J Infect Dis; 2006; 38(2):152-4. PubMed ID: 16449014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple relapses of visceral leishmaniasis in an adolescent with idiopathic CD4+ lymphocytopenia associated with novel immunophenotypic and molecular features.
    Prigione I; Castagnola E; Imberti L; Gambini C; Gradoni L; Dianzani U; Ramenghi U; Giacopelli F; Moretta A; Moretta L; Plebani A; Fischer A; Pistoia V
    Pediatr Infect Dis J; 2009 Feb; 28(2):161-3. PubMed ID: 19106781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B for the treatment of visceral leishmaniasis.
    Bern C; Adler-Moore J; Berenguer J; Boelaert M; den Boer M; Davidson RN; Figueras C; Gradoni L; Kafetzis DA; Ritmeijer K; Rosenthal E; Royce C; Russo R; Sundar S; Alvar J
    Clin Infect Dis; 2006 Oct; 43(7):917-24. PubMed ID: 16941377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of antimony resistant kala-azar cured with amphotericin B].
    Chen SB; Yang CM; Zhang CJ
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767
    [No Abstract]   [Full Text] [Related]  

  • 11. The treatment of kala-azar: old and new options.
    Zijlstra EE
    Trop Geogr Med; 1992 Jul; 44(3):288. PubMed ID: 1455546
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful treatment of visceral leishmaniasis with fluconazole and allopurinol in a patient with renal failure.
    Colakoglu M; Fidan Yaylali G; Yalcin Colakoglu N; Yilmaz M
    Scand J Infect Dis; 2006; 38(3):208-10. PubMed ID: 16500783
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of visceral leishmaniasis.
    Wali JP; Sharma SK; Guleria JS
    J Assoc Physicians India; 1984 Sep; 32(9):813-4. PubMed ID: 6096351
    [No Abstract]   [Full Text] [Related]  

  • 14. A tumor lysis-like syndrome during therapy of visceral leishmaniasis.
    Liberopoulos E; Alexandridis G; Elisaf M
    Ann Clin Lab Sci; 2002; 32(4):419-21. PubMed ID: 12458897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly effective oral amphotericin B formulation against murine visceral leishmaniasis.
    Wasan KM; Wasan EK; Gershkovich P; Zhu X; Tidwell RR; Werbovetz KA; Clement JG; Thornton SJ
    J Infect Dis; 2009 Aug; 200(3):357-60. PubMed ID: 19545212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphotericin B in visceral leishmaniasis.
    Giri OP
    Indian Pediatr; 1993 Jan; 30(1):74-8. PubMed ID: 8406714
    [No Abstract]   [Full Text] [Related]  

  • 17. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine.
    Sundar S; Rai M; Chakravarty J; Agarwal D; Agrawal N; Vaillant M; Olliaro P; Murray HW
    Clin Infect Dis; 2008 Oct; 47(8):1000-6. PubMed ID: 18781879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P; Sundar S
    Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deadly parasitic disease grips southern Sudan.
    Gulland A
    BMJ; 2002 Nov; 325(7373):1133. PubMed ID: 12433757
    [No Abstract]   [Full Text] [Related]  

  • 20. ABLE: a new and improved amphotericin B for visceral leishmaniasis?
    Berman J
    Am J Trop Med Hyg; 2009 May; 80(5):689-90. PubMed ID: 19407106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.